Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SENTI-202-101: a Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects with CD33 And/or FLT3 Expressing Malignancies

Next Previous
Trial Profile

SENTI-202-101: a Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects with CD33 And/or FLT3 Expressing Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SENTI-202 (Primary) ; Cytarabine; Fludarabine
  • Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man
  • Acronyms SENTI-202-101
  • Sponsors Senti Biosciences

Most Recent Events

  • 22 May 2025 According to a Senti Biosciences media release, the company reported the receipt of an additional $1.0 million from the California Institute of Regenerative Medicine (CIRM) upon the achievement of clinical study enrollment milestones.
  • 30 Apr 2025 Interim results (n=6; as of 6 Jan 2025) presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 30 Apr 2025 Results assessing hematopoietic cell fractions in peripheral blood (PB) & bone marrow (BM) from relapsed/refractory (R/R) AML patients presented at the 116th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top